EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Age‐associated differences in the breast cancer immune microenvironment

Rasmus Oc Humlevik iD, Ying Chen, Tor A Klingen, Anna Km Sæle iD, Amalie A Svanøe, Ulrikke Hugaas iD, Amalie B Kvamme iD, Amalie F Tegnander iD, Ingeborg Winge iD, Turid Aas, Anette Heie, Lars A Akslen iD und 2 weitere

The Journal of Pathology: Clinical Research · 2026-11 · 12 (6)

DOI: 10.1002/2056-4538.70115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 03.11.2026. Verfasst von Rasmus Oc Humlevik und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Tumor Microenvironment, Lymphocytes, Tumor-Infiltrating, Breast Neoplasms. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Forskningsråd, Helse Vest.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Young age is associated with poorer outcomes and more aggressive clinicopathological features in breast cancer, but the biological underpinnings are incompletely understood. With the emergence of infiltrating immune cell tissue‐based biomarkers, we aimed to investigate a relation to age by mapping of CD45, CD3, CD8, FOXP3, and CD163 positive cells. We examined a population‐based cohort of women under the age of 50 years (BCY‐B cohort, n = 311) in comparison to a previously reported series of patients aged 50–69 (TBC cohort, n = 282) years. The BCY‐B cohort was additionally stained for two PD‐L1 markers. Young age (under 50 years) was not associated with higher levels of tumor‐infiltrating lymphocytes (TILs), represented by markers such as CD45 and CD3. However, younger patients presented with lower levels of FOXP3‐positive TILs, both in luminal and non‐luminal subgroups, and higher levels of CD163‐positive tumor‐associated macrophages (TAMs) in combined analyses only. CD163 showed prognostic value when analyzing all patients together and within the luminal subgroups. For non‐luminal subgroups, CD3 expression was prognostic, while CD8 expression showed a trend. Notably, no age‐associated difference in prognostic value was observed for any marker. Among patients within the BCY‐B cohort (aged under 50 years), those below 40 years demonstrated higher PD‐L1 tumor cell expression, also within the triple‐negative subgroup, when compared to those aged 40–49 years. In conclusion, our study found only limited differences in tumor‐infiltrating immune cells with age, with higher density of FOXP3‐positive TILs in patients aged 50 years or above. Within the BCY‐B cohort (age under 50), patients aged under 40 years showed higher tumor expression of PD‐L1 when compared to those aged 40–49 years, suggesting age‐associated differences in immune checkpoint regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentLymphocytes, Tumor-InfiltratingBreast NeoplasmsHumansFemaleMiddle AgedAge FactorsForkhead Transcription FactorsAgedAdultAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenBiomarkers, TumorB7-H1 AntigenReceptors, Cell SurfaceTumor-Associated MacrophagesLeukocyte Common AntigensCD3 Complex

Stichwörter der Autor:innen

CD163FOXP3PD‐L1TAMsTILsTregsbreast cancerimmune cellstumor immune microenvironmentyoung age

Substanzen

Forkhead Transcription FactorsAntigens, CDFOXP3 protein, humanAntigens, Differentiation, MyelomonocyticCD163 AntigenBiomarkers, TumorB7-H1 AntigenReceptors, Cell SurfaceLeukocyte Common AntigensCD274 protein, human

Autor:innen und Institutionen

  • Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Department of Pathology, Haukeland University Hospital, Bergen, Norway.
  • Fürst Medical Laboratorium, Oslo, Norway.
  • Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
  • Department of Pathology, Vestfold Hospital, Tønsberg, Norway.
  • Department of Surgery, Haukeland University Hospital, Bergen, Bergen, Norway.

ORCID-Profile: Rasmus Oc Humlevik, Anna Km Sæle, Ulrikke Hugaas, Amalie B Kvamme, Amalie F Tegnander, Ingeborg Winge, Lars A Akslen, Elisabeth Wik, Erling A Hoivik

Förderung

  • Norges Forskningsråd
  • Helse Vest

Zitieren

APA

Humlevik, R. O., Chen, Y., Klingen, T. A., Sæle, A. K., Svanøe, A. A., Hugaas, U., Kvamme, A. B., Tegnander, A. F., Winge, I., Aas, T., Heie, A., Akslen, L. A., Wik, E., & Hoivik, E. A. (2026). Age‐associated differences in the breast cancer immune microenvironment. The Journal of Pathology: Clinical Research, 12(6). https://doi.org/10.1002/2056-4538.70115

Vancouver

Humlevik RO, Chen Y, Klingen TA, Sæle AK, Svanøe AA, Hugaas U, et al. Age‐associated differences in the breast cancer immune microenvironment. The Journal of Pathology: Clinical Research. 2026;12(6). doi:10.1002/2056-4538.70115

BibTeX
@article{Humlevik2026,
  author = {Humlevik, Rasmus Oc and Chen, Ying and Klingen, Tor A and Sæle, Anna Km and Svanøe, Amalie A and Hugaas, Ulrikke and Kvamme, Amalie B and Tegnander, Amalie F and Winge, Ingeborg and Aas, Turid and Heie, Anette and Akslen, Lars A and Wik, Elisabeth and Hoivik, Erling A},
  title = {Age‐associated differences in the breast cancer immune microenvironment},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2026},
  volume = {12},
  number = {6},
  doi = {10.1002/2056-4538.70115}
}
Kostenlos starten →